Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau.
Ya-Bing CaoHongtao ChenYaobin HuangHao HuPublished in: Cancer reports (Hoboken, N.J.) (2019)
Our findings demonstrate clinical benefit of olaparib to mainland Chinese patients with high-grade SOC, particularly for patients with BRCA mutations and who require maintenance therapy.